ABIVAX Société Anonyme (AAVXF)
PNK · Healthcare · Biotechnology
$101.25
+0.00%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$8.08B
Shares Outstanding
79.8M
Exchange
PNK
Currency
USD
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -46.5M | -80.7M | -71.6M | -56.2M |
| Net Income | -48.4M | -153.4M | -82.0M | -48.5M |
| Diluted EPS | $-0.76 | $-2.10 | $nan | $-0.61 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -50.8M | |||
| Operating Income | -51.2M | -127.4M | -173.0M | -246.1M |
| Net Income | -60.7M | -147.7M | -176.2M | -336.1M |
| Diluted EPS | $-3.18 | $-3.43 | $-2.78 | $-4.83 |